Category: News

IRVINE, Calif., March 09, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake… Continue reading Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023

IRVINE, Calif., Feb. 02, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma ConferenceDate: Wednesday, Feb. 15,… Continue reading Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference

IRVINE, Calif., Jan. 31, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted mavodelpar (REN001) Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of… Continue reading Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

IRVINE, Calif., Nov. 08, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September 30, 2022. “We continued to advance our REN001 development programs during the third quarter,” said Gregory… Continue reading Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

IRVINE, Calif., Nov. 03, 2022 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at three upcoming healthcare conferences. Jefferies Global Healthcare Conference Date: November 15 – 17, 2022Location:… Continue reading Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

IRVINE, Calif., Sept. 06, 2022 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the following conferences in September, as detailed below: Baird Global Healthcare Conference (September 13-14,… Continue reading Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, announced two poster presentations at the International Network for Fatty Acid Oxidation Research and Management (INFORM) annual meeting, being held in Freiburg, Germany August… Continue reading Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

IRVINE, Calif., Aug. 09, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended June 30, 2022. “The second quarter was a very productive period for the company, highlighted by advancements… Continue reading Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

IRVINE, Calif., Aug. 02, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the company’s Board of Directors. “Roshawn is an accomplished leader within the biopharma industry,” said Mike… Continue reading Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

LC-FAOD program to move forward into the next stage of clinical development Enrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects on track to be completed year-end 2022 Alignment with European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA); single pivotal trial for registration of REN001… Continue reading Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates